Drug Details
| General Information of the Drug (ID: DR2742) | ||||
|---|---|---|---|---|
| Name |
Celecoxib
|
|||
| Synonyms |
CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Rheumatoid arthritis [ICD-11: FA20] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Elimination
2% of drug is excreted from urine in the unchanged form
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.48915 micromolar/kg/day
Water Solubility
The ability of drug to dissolve in water is measured as 0.005 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C17H14F3N3O2S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
|
|||
| InChI |
1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
|
|||
| InChIKey |
RZEKVGVHFLEQIL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 169590-42-5
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Allyl isothiocyanate | Armoracia rusticana | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PTGER2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | AY-27 | CVCL_S825 | Rat urinary system neoplasms | Rattus norvegicus | ||
| In-vivo Model | Female F344 rats (Harlan) at 9-10 weeks of age were anesthetized with ketamine and xylazine. | |||||
| Experimental
Result(s) |
The combination regime was more effective than each single agent in inhibiting microvessel formation and stimulating microvessel maturation in the tumor tissues. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Aberrant crypt foci (ACF) animal model was induced by subcutaneously injecting 0.2 ml DMH (30 mg/kg b.w.) in male, 6-week-old, F344 rats. | |||||
| Experimental
Result(s) |
Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. | |||||
| Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | COLO 357 | CVCL_0221 | Pancreatic adenosquamous carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
EGCG synergistically boosts celecoxib-mediated effects and reduces the levels of celecoxib required to elicit beneficial effects on tumorigenic mediators by a factor of ten. | |||||
| Gamma tocotrienol | Bixa orellana | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | +SA mammary epithelial cells' | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Combined low dose treatment of Gamma-tocotrienol and celecoxibthe showed synergistic antiproliferative effects of against +SA mammary tumor cells in culture. | |||||
| Levodopa | Mucuna pruriens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Parkinsonian rats were used as animal model in this study. | |||||
| Experimental
Result(s) |
L-DOPA + celecoxib combination produces an antiallodynic and antihyperalgesic synergistic interaction at the systemic level, and these effects are mediated, at the central level, through activation of the NO-cGMP-ATP-sensitive K+ channel pathway. | |||||
| Luteolin | Abrus precatorius | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | MDA-MB-231 cells (2*107) were inoculated subcutaneously into the right flanks of female BALB/c nude mice (6-7 weeks old). | |||||
| Experimental
Result(s) |
Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells. | |||||
| Piperine | Piper nigrum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | WNT3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | WNT5A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| In-vivo Model | CT26.WT (5*106) cells were inoculated subcutaneously in female Balb/c mice. | |||||
| Experimental
Result(s) |
Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway. | |||||
| Plumbagin | Plumbago europaea | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | UACC-903 | CVCL_4052 | Cutaneous melanoma | Homo sapiens | ||
| Mel JuSo | CVCL_1403 | Cutaneous melanoma | Homo sapiens | |||
| A375-M | CVCL_B222 | Amelanotic melanoma | Homo sapiens | |||
| 1205Lu | CVCL_5239 | Melanoma | Homo sapiens | |||
| FF2441 | Healthy | Homo sapiens | ||||
| In-vivo Model | Subcutaneous injection of 1.0 * 106 UACC 903 or 1205 Lu melanoma cells were injected above both the left and right rib cages of 4-5 week-old female Athymic-Foxn1nu nude mice. | |||||
| Experimental
Result(s) |
Combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cell were dependent for survival. | |||||
| Resveratrol | Gnetum parvifolium | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [11] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| In-vivo Model | Mammary carcinogenesis was initiated with two intra peritoneal doses (50 mg/kg body weight each) of N-methyl-N-nitrosourea (NMU) dissolved in a physiological NaCl solution. | |||||
| Experimental
Result(s) |
Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. | |||||
| Gamma tocotrienol + Vitamin E | Click to Show/Hide the Molecular Data of This NP | |||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | +SA mammary epithelial cells' | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Combination therapy with these agents may provide enhanced therapeutic response in breast cancer patients, while avoiding the toxicity associated with high-dose COX-2 inhibitor monotherapy. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Honokiol | Magnolia officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [12] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | FOXM1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | FOXP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ITGAM | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MKI67 | Molecule Info | |||
| Down-regulation | Expression | NNT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PECAM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
| Experimental
Result(s) |
The combined treatment with PV-CXB and PV-HNK showed synergistic effect both in vitro and in vivo. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Prostaglandin G/H synthase 2 (COX-2) | Molecule Info | [13] | |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
| 2 | Aspirin triggered resolvin D biosynthesis | |||
| 3 | C20 prostanoid biosynthesis | |||
| 4 | Aspirin triggered resolvin E biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| 3 | NF-kappa B signaling pathway | |||
| 4 | VEGF signaling pathway | |||
| 5 | TNF signaling pathway | |||
| 6 | Retrograde endocannabinoid signaling | |||
| 7 | Serotonergic synapse | |||
| 8 | Ovarian steroidogenesis | |||
| 9 | Oxytocin signaling pathway | |||
| 10 | Regulation of lipolysis in adipocytes | |||
| 11 | Leishmaniasis | |||
| 12 | Pathways in cancer | |||
| 13 | Chemical carcinogenesis | |||
| 14 | MicroRNAs in cancer | |||
| 15 | Small cell lung cancer | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TSH Signaling Pathway | |||
| 3 | IL4 Signaling Pathway | |||
| 4 | TGF_beta_Receptor Signaling Pathway | |||
| 5 | IL5 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | Click to Show/Hide | ||
| 2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 3 | Toll receptor signaling pathway | |||
| 4 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | Click to Show/Hide | ||
| 2 | S1P1 pathway | |||
| 3 | C-MYB transcription factor network | |||
| 4 | Signaling mediated by p38-alpha and p38-beta | |||
| 5 | Calcium signaling in the CD4+ TCR pathway | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
| 2 | Arachidonic acid metabolism | |||
| 3 | Aryl Hydrocarbon Receptor | |||
| 4 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 5 | Spinal Cord Injury | |||
| 6 | Integrated Pancreatic Cancer Pathway | |||
| 7 | Eicosanoid Synthesis | |||
| 8 | Selenium Micronutrient Network | |||